PRASAD SUYASH (CMO and Head of R&D) sold 2.4% of their position (12.86K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market sale worth $47.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 7/7/2022ACC: 0001209191-22-041455
Officer· CMO and Head of R&D
Since Sep 2020
-12.86K
Net shares
Net seller
$47.6K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
12.86K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−3.90K
Price / share
$3.51
Trade value
$13.71K
% of position
0.7%
7/5/2022
543.45K→539.54K
Common Stock
Direct
Shares
−8.96K
Price / share
$3.79
Trade value
$33.94K
% of position
1.7%
7/6/2022
539.54K→530.59K
Total
Net shares
−12.86K
Net value
-$47.65K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/5/2022 | S · Sale | −3.90K | $3.51 | $13.71K | 0.7% | 543.45K | 539.54K |
| Common Stock Direct | 7/6/2022 | S · Sale | −8.96K | $3.79 | $33.94K | 1.7% | 539.54K | 530.59K |
| Total | −12.86K | -$47.65K | ||||||
Derivative Transactions0
No derivative transactions reported